Dextromethorphan-Bupropion: Auvelity Uses, Interactions and Treatment Review

The FDA initially approved Auvelity for adult major depressive disorder in 2022. On April 30, 2026, it approved an additional use for agitation associated with dementia due to Alzheimer’s disease in adults. The latter is not a treatment for Alzheimer’s memory loss, a cure for dementia or an as-needed rescue medicine. Authorization in one country does not establish availability or the same approved use elsewhere. [1]

Ask the prescriber to name the condition being treated and the specific symptoms being followed. Someone receiving treatment for depression needs a different assessment from a person with dementia whose behavior has changed. A brand name can be the same while the goals, starting instructions, monitoring needs and people involved in care differ substantially.

Dextromethorphan affects NMDA and sigma-1 signaling. Bupropion is an antidepressant and inhibits CYP2D6, slowing dextromethorphan metabolism and increasing its exposure. The exact therapeutic mechanism is not fully established. This does not mean that a person’s symptoms can be explained by a single chemical deficiency, or that the effect of the combination can be predicted from taking either ingredient alone. [2]

Do not try to reproduce Auvelity by combining a cough remedy with an existing bupropion prescription. Products differ in concentration, release characteristics and additional ingredients. Such experimentation bypasses the interaction and seizure-risk assessment that should accompany the actual prescription. Bring all cough, cold and psychiatric medicines to the pharmacist before adding anything new.

For depression, discuss the previous treatment history, the reason this option is being considered and how benefit will be evaluated. Record mood, interest, concentration and everyday functioning rather than looking only for a rapid subjective sensation. Improvement in a study population does not guarantee the same speed or extent of response for an individual.

Agree when the first review will occur and what would justify an earlier call. Include psychotherapy, sleep and social support in the plan where appropriate. A medicine change should not leave unresolved questions about who manages a deterioration or whether another antidepressant is being continued. The depression medication hub explains how different treatment roles fit into a broader review.

Before treating distress in a person with dementia, NICE recommends assessment for clinical and environmental causes, including pain, delirium and unsuitable care arrangements. Psychosocial and environmental support remains part of management. A new medication indication does not remove those steps. Sudden confusion or a marked acute change may require urgent medical assessment rather than simply a behavioral prescription. [3]

Caregivers can prepare useful observations: what happens, when it occurs, possible triggers, changes in sleep or physical comfort and what helps. Avoid vague labels such as difficult behavior. The person living with dementia should remain involved to the extent possible, with consent and decision-making support handled appropriately. Medication should have a clearly described target and an agreed review of benefit and harm.

Auvelity is an extended-release tablet and should be swallowed whole. Current US labeling includes more than one strength and different treatment instructions for its indications. Kidney function, interacting medicines and CYP2D6 metabolism may alter prescribing. Do not copy another patient’s schedule or assume that a depression prescription is the correct starting plan for dementia-related agitation. [2]

Ask the pharmacist to check the package against the written plan after any change. Keep an accurate record of what was actually taken, especially if a caregiver administers medicines. A missed dose is not a reason to double up independently. When instructions are unclear, obtain clarification rather than modifying the tablet or guessing from the strength printed on it.

The combination is contraindicated in seizure disorders, current or previous bulimia or anorexia nervosa, and abrupt discontinuation of alcohol, benzodiazepines, barbiturates or certain antiseizure medicines. Other factors may also increase seizure risk. A seizure during treatment requires immediate assessment; the product labeling directs discontinuation without restarting. These precautions are especially relevant when depression and substance-use problems coexist. [2]

Tell the clinician about previous eating disorders even if symptoms have improved, and about actual alcohol or sedative use. Do not abruptly stop those substances in an attempt to become eligible for the medicine. The withdrawal problem needs its own safe clinical plan. An honest history allows the team to consider a suitable alternative rather than discovering a contraindication after treatment starts.

Dizziness, drowsiness, nausea, dry mouth, gastrointestinal symptoms, sweating, sleep disturbance and sexual problems are reported effects. New suicidal thoughts, unusual activation, hallucinations or marked mood changes need prompt assessment. Do not drive while impaired. Antidepressant monitoring is particularly important early in treatment and around changes, but unexpected deterioration at any stage should be reported. [4]

Describe an adverse effect in terms of its impact: inability to work safely, disrupted sleep or reduced food intake. In dementia care, caregivers may notice falls, new confusion or reduced participation rather than a verbal complaint. These observations help distinguish improvement in the target symptom from a change caused mainly by sedation or another unwanted effect.

MAO inhibitors are incompatible with Auvelity and require a prescriber-managed interval when switching. Other serotonergic drugs, CYP2D6-related interactions and medicines that lower the seizure threshold need review. Duplicate bupropion or dextromethorphan exposure can be harmful. Provide prescription, non-prescription and herbal products, including anything used only occasionally. [4]

Do not stop or substitute another psychiatric medicine on your own. The prescribing team should state which treatment continues, which changes and who monitors the transition. Keep those instructions together with the medicine list. A pharmacist can help identify a cough product’s ingredients without requiring you to interpret a complicated label unaided.

Bupropion can raise blood pressure, and Auvelity requires baseline and ongoing blood-pressure assessment. Kidney and liver health, glaucoma risk and pregnancy or breastfeeding can change suitability. The current US label advises against breastfeeding during treatment and for a period after the last dose; the prescriber should explain the applicable instructions. A psychiatric prescription does not make physical-health monitoring optional. [2]

Bring recent test results and tell the team about changes in other medical care. Ask who will arrange monitoring and how the results will be communicated. When several clinicians are involved, do not assume that each has automatically received the others’ records. A short written follow-up plan can prevent a requested check from being missed.

Auvelity is not an alcohol, benzodiazepine or opioid detox treatment. Bupropion’s role in some smoking-cessation products does not automatically transfer to this combination. Dextromethorphan has misuse potential, and taking more to seek a psychoactive effect is dangerous. Raise concerns about uncontrolled use without waiting for an overdose. [5] [6]

Routine stopping or switching should be discussed with the prescriber. Describe new symptoms after a change rather than assuming they prove either addiction or relapse. A continuing plan should address the original condition, any co-occurring substance-use problem and how to obtain help. The aim is coordinated treatment, not simply completing a medicine-free interval.

Ask what specific problem is being treated, how it will be measured and what degree of improvement would justify continuing. Clarify which unwanted effects should prompt a same-day call and which require emergency care. For dementia-related agitation, ask how pain, infection, delirium and environmental triggers were considered before the prescription.

Choose a few observations to bring to each appointment rather than trying to record every moment. For depression, this may include concentration, enjoyment and ability to complete daily tasks. For agitation, describe frequency, context and severity in plain language. Keep the person’s preferences and comfort visible in the record, not only the burden on others.

Is Auvelity just cough medicine?

No. It is a specific prescription combination with a pharmacokinetic interaction between its ingredients. Over-the-counter dextromethorphan products are not substitutes and may contain additional active ingredients.

Is it an as-needed medicine for agitation?

No. The US Alzheimer-related agitation indication specifically excludes as-needed use. Sudden dangerous behavior or acute confusion requires assessment rather than an extra tablet.

Does one approval apply everywhere?

No. Ask about the actual country’s authorization, the supplied formulation and the reason for any off-label proposal. A listing in this directory is not a statement that Cogniful supplies or prescribes the product.

Write the treatment purpose beside the medicine name in the care record. For example, record whether the prescriber is targeting major depression or a defined pattern of Alzheimer-related agitation. This prevents later readers from assuming that a shared brand means a shared diagnosis. It also gives the next appointment a clear starting point: is the intended problem improving, and at what cost in unwanted effects?

When a caregiver helps administer treatment, agree how observations will be communicated and how the patient’s preferences will be represented. Record changes in comfort, engagement and daily functioning, not only whether behavior is easier for other people to manage. Ask who will reassess the prescription if the original target has changed. A useful follow-up plan should remain understandable to the patient, caregiver, pharmacist and prescribing clinician rather than depending on one person’s memory of the consultation.

1. FDA: Auvelity expanded indication, April 30, 2026.
2. DailyMed: Current Auvelity prescribing information.
3. NICE NG97: Dementia assessment and management.
4. MedlinePlus: Dextromethorphan and bupropion.
5. Auvelity: Manufacturer patient information.
6. MedlinePlus: Bupropion.